Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Masked, Vehicle-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of OTX-DED (Dexamethasone Intracanalicular Ophthalmic Insert) for the Short-Term Treatment of Signs and Symptoms of Dry Eye Disease (DED)
Conditions
Interventions
OTX-DED
OTX-DED
+1 more
Locations
15
United States
Ocular Therapeutix
Inglewood, California, United States
Ocular Therapeutix, Inc
Mission Hills, California, United States
Ocular Therapeutix, Inc.
Newport Beach, California, United States
Ocular Therapeutix, Inc.
Santa Ana, California, United States
Ocular Therapeutix, Inc.
Delray Beach, Florida, United States
Ocular Therapeutix, Inc.
Largo, Florida, United States
Start Date
February 12, 2021
Primary Completion Date
August 11, 2021
Completion Date
September 22, 2021
Last Updated
February 22, 2023
NCT07463950
NCT07363824
NCT07396441
NCT07298811
NCT07295691
NCT07191847
Lead Sponsor
Ocular Therapeutix, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions